ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 8

CKD-506, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, Regulates Inflammatory Responses Through NF-kB and AP-1 Signaling

Jieun Shin1, Nina Ha 1, Daekwon Bae 1, Dong-hyeon Suh 1, Ji-yeon Baek 1, Jae Hyun Jun 1, Yong Jae Lee 1, Young Il Choi 1, Keun Ho Ryu 1, Gi Soo Youn 2 and Jinseu Park 3, 1CKD Research Institute, Yongin-si, Republic of Korea, 2Department of Biomedical Science, Hallym University, Chuncheon, Republic of Korea, 3Department of Biomedical Science, Hallym University, Chuncheon

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Histone deacetylase 6, inflammation and CKD-506

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Cytokines & Cell Trafficking Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Inhibition of HDAC6 has been proposed beneficial and therapeutic effects in inflammatory diseases. CKD-506, a potent and selective oral HDAC6 inhibitor, has anti-inflammatory and anti-rheumatic effects in arthritis animal models and RA patient samples. Moreover, CKD-506 was generally safe and well tolerated following single and multiple doses in healthy volunteers, and CKD-506 is on clinical investigation to assess the efficacy and safety in patients with rheumatoid arthritis. Herein, we identify the molecular mechanisms of CKD-506 in regulation of inflammation.

Methods: Mouse peritoneal macrophages and Raw264.7 cells were transfected with HDAC6 overexpression vector or pcDNA3.1 vector as control. Cells were cultured in the presence or absence of 0.03~3 μM CKD-506, and the expression and production of inflammatory mediators were determined by RT-PCR and ELISA respectively. For reporter assays, cells were transfected with pNF-kB-luc or pAP-1-luc plasmid and luciferase activity in cell lysates was determined by luminometer. Tubulin acetylation and signaling molecules by CKD-506 in HDAC6 overexpressed cells were checked by immunoblot analysis.

Results: HDAC6 overexpression in both Raw264.7 cells and mouse peritoneal macrophages strongly induced pro-inflammatory mediators such as TNFa, IL-6, IL-1b. However, CKD-506 inhibited the expression and production of TNFa, IL-6, and IL-b at dose dependent manners in HDAC6 overexpressed cells. Moreover, ROS production and NADPH oxidase activity mediated by HDAC6 overexpression were inhibited by CKD-506. In signaling pathway, HDAC6 overexpression strongly induced NF-kB and AP-1 activity and CKD-506 inhibited both signaling pathways. In addition, CKD-506 with methotrexate exhibited better anti-inflammatory effects on macrophages with HDAC6 overexpression.

Conclusion: CKD-506 inhibits inflammatory mediators such as TNFa, IL-6, IL-1b, ROS, and NADPH oxidase activity in HDAC6 overexpressed cells. This anti-inflammatory activities of CKD-506 are mediated through NF-kB and AP-1.


Disclosure: J. Shin, None; N. Ha, None; D. Bae, None; D. Suh, None; J. Baek, None; J. Jun, None; Y. Lee, None; Y. Choi, None; K. Ryu, None; G. Youn, None; J. Park, None.

To cite this abstract in AMA style:

Shin J, Ha N, Bae D, Suh D, Baek J, Jun J, Lee Y, Choi Y, Ryu K, Youn G, Park J. CKD-506, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, Regulates Inflammatory Responses Through NF-kB and AP-1 Signaling [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/ckd-506-a-selective-histone-deacetylase-hdac-6-inhibitor-regulates-inflammatory-responses-through-nf-kb-and-ap-1-signaling/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ckd-506-a-selective-histone-deacetylase-hdac-6-inhibitor-regulates-inflammatory-responses-through-nf-kb-and-ap-1-signaling/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology